Figure 3.

Dinaciclib additively enhanced anti-MM effect of DOX by augmenting DOX-triggered senescence rather than apoptosis. (A) RPMI-8226 cells treated with dinaciclib for 24 h were extracted and proteins were incubated with primary antibodies against CDK1/2/5/9. GAPDH was used as a loading control. RPMI-8226 cells were treated with DMSO, 100 nM DOX, 5 nM dinaciclib, or both for 24 h. Cell viability (B), apoptotic cells (C) and senescence-associated β-gal (D) was measured. Data were obtained from at least three independent experiments. Differences between multiple groups was confirmed using one-way analysis of variance followed by Tukey's post hoc test. *P<0.05 as indicated. DOX, doxorubicin; CDK, cyclin-dependent kinase.